Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia

Clinical Therapeutics

Volumn 21, Issue 5, 1999, Pages 841-852

  Mulenga, Modest ^a   Sukwa, Thomas Y ^a   Canfield, Craig J ^b   Hutchinson, David B A ^c,d  

^a TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^b Pharmaceutical System Inc   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Atovaquone; Plasmodium falciparum malaria; Proguanil; Pyrimethamine; Sulfadoxine

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; FANSIDAR;

ADOLESCENT; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARASITEMIA; PHASE 3 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRURITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033045555     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80006-X     Document Type: Article

References (28)

1. 1. Boudreau EF, Ekue JM, Sheth UK. Curative treatment of P falciparum infections in school children: A controlled comparative study between Fansimef and chloroquine. Geneva: World Health Organization; August 1989. WHO/CHEMAL Study Report.
2. 2. Boudreau EF, Ekue JM, Kawasha J. A Phase III comparative clinical trial of four regimens of halofantrine and chloroquine in treatment of P falciparum malaria. Geneva: World Health Organization; September 1993. WHO/CHEMAL Study Report.
3. 3. Ekue JM, Phiri DE, Sheth UK, Mukunyandela M. A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. Bull WHO. 1987;65:369-373.
4. 4. Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet. 1985;ii:1072-1073.
5. 5. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar®) for malaria prophylaxis. Am J Trop Med Hyg. 1986;35: 451-458.
6. 6. Zitelli BJ, Alexander J, Taylor S, et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar®). Ann Intern Med. 1987;106:393-395.
7. 7. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg. 1991;45:86-91.
8. 8. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: An overview of spontaneous reports of severe psychiatric reactions and convulsions. Am J Trop Med Hyg. 1992;95: 167-179.
9. 9. Nosten F, Ter Kuile OF, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993; 341:1034-1056.
10. 10. Monlun E, le Metayer P, Szwandt S, et al. Cardiac complications of halofantrine: A prospective study of 20 patients. Trans R Soc Trop Med Hyg. 1995;89:430-433.
11. 11. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992;43:1545-1553.
12. 12. Dollery C. Proguanil (hydrochloride). In: Dollery C, ed. Therapeutic Drugs. Vol 2. New York: Churchill Livingstone; 1991: 247-251.
13. 13. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol. 1995; 80:373-381.
14. 14. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54:62-66.
15. 15. Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996; 347:1511-1514.
16. 16. de Alencar FE, Cerutti C Jr, Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis. 1997;175:1544-1547.
17. 17. Rolan PE, Mercer AJ, Weatherly BC, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol. 1994;37:13-20.
18. 18. World Health Organisation. Advances in malaria chemotherapy. WHO Tech Rep Ser. 1973;529:30-32.
19. 19. Smith PG, Morrow RH, eds. Methods for Field Trials of Interventions Against Tropical Diseases. Oxford, England: Oxford University Press; 1991:283.
20. 20. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria. Am J Trop Med Hyg. 1999; 60:533-541.
21. 21. Bustos DG, Canete-Miguel E, Canfield CJ, Hutchinson DBA. Atovaquone/proguanil compared with chloroquine and chloroquine/sulfadoxine/pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis. In press.
22. 22. Wolday D, Kibreab T, Bukenya D, Hodes R. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg. 1995;89:654-656.
23. 23. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Plasmodium falciparum: Susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren. Trans R Soc Trop Med Hyg. 1994;88:440-442.
24. 24. Benito A, Roche J, Molina R, et al. In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea. Am J Trop Med Hyg. 1995;53:526-531.
25. 25. Kamugisha J, Kipp W, Burnham G. In vivo sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and sulfadoxine-pyrimethamine in western Uganda. Trop Geogr Med. 1994;46:364-365.
26. 26. Barat LM, Bloland PB. Drug resistance among malaria and other parasites. Infect Dis Clin North Am. 1997;11:969-987.
27. 27. Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 1998;27:494-499.
28. 28. Lell B, Luckner D, Ndjave M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998;351:709-713.